Benjamin L. Palleiko - 21 Feb 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Benjamin L. Palleiko
Issuer symbol
KALV
Transactions as of
21 Feb 2025
Net transactions value
$0
Form type
4
Filing time
25 Feb 2025, 20:36:38 UTC
Previous filing
19 Feb 2025
Next filing
10 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KALV Restricted Stock Unit Award $0 +372,000 $0.000000 372,000 21 Feb 2025 Common Stock 372,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F2 1/16th of the total number of shares underlying the RSUs shall vest on each quarterly anniversary of the Vesting Commencement Date thereafter, for so long as grantee's Service (as defined in the Plan) does not terminate.